Written by Peter Liu
Spoon Feed
There is growing evidence that direct oral anticoagulant (DOAC) therapy is at least as effective as warfarin for left ventricular (LV) thrombus.
LV thrombus – DOACs OK
LV thrombus is a rare but clinically significant complication of myocardial infarction and heart failure, associated with elevated risks of stroke and systemic emboli. While the 2013 AHA STEMI guidelines specified warfarin as the most established anticoagulant for LV thrombus, these guidelines are now outdated, and DOAC therapy is a reasonable alternative due to the following evidence.
- Meta-analyses of small RCTs show DOAC therapy to be noninferior.
- Observational trials sometimes show DOACs to have a favorable bleeding and stroke risk, though these benefits are not reproducibly demonstrated in all meta-analyses.
The TriNetX Registry study, a retrospective cohort analysis, strengthens the evidence base for DOAC use for LV thrombus. Among 39,770 propensity-matched patients, DOACs significantly reduced stroke (11.8% vs. 13.7%; RR 0.86, 95%CI 0.82-0.91 ), systemic embolism (3.5% vs. 4.2%; RR 0.84, 95%CI 0.76-0.93), and major bleeding (4.8% vs. 5.3%; RR 0.90, 95%CI 0.83-0.98) when compared to VKAs. Benefits were consistent across ACS and non-ACS subgroups with dabigatran, apixaban, edoxaban, and rivaroxaban all presented.
While the absence of a large-scale RCT limits definitive conclusions, this study adds weight to the view that DOACs offer at least comparable efficacy and safety to warfarin therapy for LV thrombus.
How does this change my practice?
There are now only a few domains where warfarin is generally superior to DOACs: mechanical heart valves, rheumatic atrial fibrillation, and thrombotic antiphospholipid syndrome. Other areas of uncertainty include decompensated cirrhosis, severe renal disease, and scattered conditions such as LV thrombus and portal vein thrombosis. In the case of LV thrombus, specifically, I suspect we are moving towards DOAC therapy becoming a standard therapeutic option.
Source
Comparison of Direct Oral Anticoagulants and Vitamin K Antagonists for Left Ventricular Thrombus: A Global Retrospective Study. Am J Med. 2025 Mar;138(3):468-476. doi: 10.1016/j.amjmed.2024.10.042. Epub 2024 Nov 8. PMID: 39522670
